Trials / Completed
CompletedNCT00232999
Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the effectiveness of nebulized IVX-0142, a novel anti-allergic drug, to inhibit allergen-induced airway narrowing in patients with allergic asthma and the related increased sensitivity of the airways to other substances, as well as to investigate a possible anti-inflammatory effect of the drug in the airways.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nebulized IVX-0142 |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2005-12-01
- Completion
- 2006-01-01
- First posted
- 2005-10-05
- Last updated
- 2021-11-12
Locations
3 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00232999. Inclusion in this directory is not an endorsement.